| Name | Title | Contact Details |
|---|
South Central Manufacturing is a Summersville, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Artios is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The Company is led by an experienced leadership team with world class scientific capabilities and proven expertise in DDR drug discovery, including the identification and development of the PARP inhibitor olaparib. It has a unique partnership with Cancer Research UK (CRUK), and collaborations with leading DNA repair researchers worldwide, such as The Institute of Cancer Research (ICR), London, the Netherlands Cancer Institute (NKI) and The Francis Crick Institute, London. Artios is building a pipeline of next-generation DDR programmes to target hard to treat cancers which will move into Phase 1 clinical studies in 2021. These include ATR inhibitor ART0380 for treating DDR defective tumours and the first-in-class Pol theta inhibitor ART4215 for mono therapy and combination treatments. In December 2020, Artios entered into a global three-year strategic research collaboration with Merck KGaA, Darmstadt, Germany to identify and develop precision oncology medicines targeting nucleases. Artios is backed by blue chip investors including: AbbVie Ventures, Andera Partners, Arix Bioscience plc, IP Group plc, Life Science Partners (LSP), M Ventures, Novartis Venture Fund (NVF), Pfizer Ventures and SV Health Investors. Artios is based at the Babraham Research Campus in Cambridge, UK, with an office in New York City, USA.
DM Clinical Research is a clinical research company that connects pharmaceutical and research organizations to individuals seeking to power the advancement of medicine. They specialize in multiple therapeutic areas in Phase I-IV clinical trials.
Quincy Bioscience, LLC is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Hydropothecary is a licensed producer and distributor of medical marijuana under Health Canada`s Access to Cannabis for Medical Purposes Regulations (ACMPR). We are committed to medical excellence and achieve this through our growing techniques, process control, quality assurance testing, robust research and development, and by offering an exceptional customer service experience. We are proud of our company`s remarkable growth thus far and look forward to our continued expansion with the construction of a new greenhouse which will boast an additional 250,000 sq/ft in 2018. We are constantly seeking skilled, energetic and highly focused p-professionals who would like the opportunity to be a part of our team and of an exciting industry that is constantly evolving.